PMID- 23484153
OWN - NLM
STAT- MEDLINE
DCOM- 20130903
LR  - 20220311
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2013
DP  - 2013
TI  - Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas 
      detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of 
      four methods.
PG  - 757490
LID - 10.1155/2013/757490 [doi]
LID - 757490
AB  - Anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements occur in a 
      subgroup of non-small cell lung carcinomas (NSCLCs). The identification of these 
      rearrangements is important for guiding treatment decisions. The aim of our study 
      was to screen ALK gene fusions in NSCLCs and to compare the results detected by 
      targeted resequencing with results detected by commonly used methods, including 
      fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and 
      real-time reverse transcription-PCR (RT-PCR). Furthermore, we aimed to ascertain 
      the potential of targeted resequencing in detection of ALK-rearranged lung 
      carcinomas. We assessed ALK fusion status for 95 formalin-fixed paraffin-embedded 
      tumor tissue specimens from 87 patients with NSCLC by FISH and real-time RT-PCR, 
      for 57 specimens from 56 patients by targeted resequencing, and for 14 specimens 
      from 14 patients by IHC. All methods were performed successfully on 
      formalin-fixed paraffin-embedded tumor tissue material. We detected ALK fusion in 
      5.7% (5 out of 87) of patients examined. The results obtained from resequencing 
      correlated significantly with those from FISH, real-time RT-PCR, and IHC. 
      Targeted resequencing proved to be a promising method for ALK gene fusion 
      detection in NSCLC. Means to reduce the material and turnaround time required for 
      analysis are, however, needed.
FAU - Tuononen, Katja
AU  - Tuononen K
AD  - Department of Pathology, Haartman Institute, University of Helsinki, P.O. Box 21 
      (Haartmaninkatu 3), 00014 Helsinki, Finland.
FAU - Sarhadi, Virinder Kaur
AU  - Sarhadi VK
FAU - Wirtanen, Aino
AU  - Wirtanen A
FAU - Ronty, Mikko
AU  - Ronty M
FAU - Salmenkivi, Kaisa
AU  - Salmenkivi K
FAU - Knuuttila, Aija
AU  - Knuuttila A
FAU - Remes, Satu
AU  - Remes S
FAU - Telaranta-Keerie, Aino I
AU  - Telaranta-Keerie AI
FAU - Bloor, Stuart
AU  - Bloor S
FAU - Ellonen, Pekka
AU  - Ellonen P
FAU - Knuutila, Sakari
AU  - Knuutila S
LA  - eng
GR  - 100140/WT_/Wellcome Trust/United Kingdom
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130120
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Oncogene Proteins, Fusion)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Non-Small-Cell Lung/*genetics
MH  - DNA Mutational Analysis/methods
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Lung Neoplasms/*genetics
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Real-Time Polymerase Chain Reaction/*methods
MH  - Receptor Protein-Tyrosine Kinases/*genetics
PMC - PMC3581296
EDAT- 2013/03/14 06:00
MHDA- 2013/09/04 06:00
PMCR- 2013/01/20
CRDT- 2013/03/14 06:00
PHST- 2012/09/19 00:00 [received]
PHST- 2012/12/09 00:00 [accepted]
PHST- 2013/03/14 06:00 [entrez]
PHST- 2013/03/14 06:00 [pubmed]
PHST- 2013/09/04 06:00 [medline]
PHST- 2013/01/20 00:00 [pmc-release]
AID - 10.1155/2013/757490 [doi]
PST - ppublish
SO  - Biomed Res Int. 2013;2013:757490. doi: 10.1155/2013/757490. Epub 2013 Jan 20.